Corporate Banner
Satellite Banner
Genomics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Sequenom to Develop Third-Generation Nanopore-Based Single Molecule Sequencing Technology

Published: Tuesday, September 25, 2007
Last Updated: Tuesday, September 25, 2007
Bookmark and Share
Company Acquires Rights to DNA and RNA Readout Technology That Holds Potential for Cost-Effective and Ultra Rapid Human Genome Sequencing

Sequenom, Inc. has announced that it plans to develop a third-generation single molecule nucleic acid analysis technology based on exclusive license rights from Harvard University that covers a readout system technology for single DNA molecules based on simultaneous optical probing of multiple nanopores.

This technology recently received a National Institutes of Health (NIH) three-year award for the development of a next-generation sequencing technology aiming at a sub-thousand dollar genome.

Nanopore-based single molecule readout technology is a method that can detect a single strand of DNA as it passes through a pore that is more than a thousand times smaller than the diameter of a human hair and should enable ultra-high throughput DNA analysis such as sequencing, genotyping, and RNA and epigenetic analysis on a whole genome scale.

Financial terms of the agreement include up-front fees, milestone payments and royalties on future product sales.

"We are excited to have an opportunity to collaborate with such world class institutions and researchers in developing this potentially disruptive technology," said Harry Stylli, Ph.D., Chief Executive Officer of Sequenom.

"This technology should enable us to provide highly competitive large-scale genotyping, and RNA analysis and ultimately sequencing-based solutions to the market.

Our MassARRAY® platform is the leading fine mapping/translational solution and as we continue to expand and develop new applications for the platform, we also plan to expand our market penetration into the complementary whole genome analysis/single molecule sequencing markets with this potentially redefining nanopore technology.

Near term we expect this nanopore technology to deliver large scale genotyping solutions and long term we believe it has the potential to provide a commercially viable, rapid, sub-thousand dollar human genome sequencing solution."

"As nucleic acid sequencing costs become progressively lower, it will become cost effective to replace more aspects of DNA and RNA analysis by sequencing," stated Charles Cantor, Ph.D., Chief Scientific Officer of Sequenom.

"It is strategically important for Sequenom to be able to offer customers a cost-effective sequencing option and we do not believe the new second-generation sequencing methods will achieve the needed cost effectiveness," Dr. Cantor added.

"The synergy between the required manpower skills needed to develop nanopore sequencing and our current science and engineering expertise behind our MassARRAY technology is noteworthy.

Optimizing molecular biology tools for sample preparation and optimizing software tools for fast signal processing are key requirements for nanopore sequencing and Sequenom currently has great strength and experience in these areas."

"This Nanopore-based single molecule readout technology combines solid-state nanopores and optical detection to overcome the major challenges associated with directly measuring electrical current differences between traversing molecules, challenges such as the need to wire every single pore and the very high flow rate and electrical noise that can prevent discrimination between single bases.

This technology also avoids the uncertainties associated with the development of new chemical compounds required in other approaches and does not rely on the relatively slow enzymatic incorporation of nucleotides allowing for an extremely high-throughput of millions of bases per second," said inventor and development partner Amit Meller, Ph.D., Associate Professor at the Boston University Department of Biomedical Engineering. Dr. Meller invented the technology while at the Rowland Institute of Harvard University.

"We are delighted that Sequenom will be developing this technology, which may enable the coming revolution in personalized medicine, which will greatly benefit the public's health," said Isaac Kohlberg, Chief Technology Officer of Harvard University and head of Harvard's Office of Technology Development.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Sequenom Announce New Data from a Collaborative Project with The Chinese University of Hong Kong
Next-generation noninvasive diagnostic technology shown to detect fetal down syndrome in first trimester of pregnancy.
Tuesday, December 02, 2008
Scientific News
Poor Survival Rates in Leukemia Linked to Persistent Genetic Mutations
For patients with an often-deadly form of leukemia, new research suggests that lingering cancer-related mutations – detected after initial treatment with chemotherapy – are associated with an increased risk of relapse and poor survival.
Searching Big Data Faster
Theoretical analysis could expand applications of accelerated searching in biology, other fields.
Growing Hepatitis C in the Lab
Recent discovery allows study of naturally occurring forms of hepatitis C virus (HCV) in the lab.
Inciting an Immune Attack on Cancer Cells
A new minimally invasive vaccine that combines cancer cells and immune-enhancing factors could be used clinically to launch a destructive attack on tumors.
Reprogramming Cancer Cells
Researchers on Mayo Clinic’s Florida campus have discovered a way to potentially reprogram cancer cells back to normalcy.
Genetic Overlapping in Multiple Autoimmune Diseases May Suggest Common Therapies
CHOP genomics expert leads analysis of genetic architecture, with eye on repurposing existing drugs.
Surprising Mechanism Behind Antibiotic-Resistant Bacteria Uncovered
Now, scientists at TSRI have discovered that the important human pathogen Staphylococcus aureus, develops resistance to this drug by “switching on” a previously uncharacterized set of genes.
How DNA ‘Proofreader’ Proteins Pick and Edit Their Reading Material
Researchers from North Carolina State University and the University of North Carolina at Chapel Hill have discovered how two important proofreader proteins know where to look for errors during DNA replication and how they work together to signal the body’s repair mechanism.
Fat in the Family?
Study could lead to therapeutics that boost metabolism.
Tissue Bank Pays Dividends for Brain Cancer Research
Checking what’s in the bank – the Brisbane Breast Bank, that is – has paid dividends for UQ cancer researchers.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!